Skip to main content
Noah Federman, MD, Pediatric Hematology & Oncology, Los Angeles, CA

Noah Federman MD Professor Health Sciences

Pediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology


Director, UCLA Pediatric Bone and Soft Tissue Sarcoma Program Director, UCLA CTSI - Clinical and Translational Research Center Director, UCLA CIRM Alpha Stem Cell Clinic Professor, Department of Pediatrics and Orthopaedic Surgery, UCLA School of Medicine

Join to View Full Profile
  • 10833 Le Conte Ave., A2-410 MDCLos Angeles, CA 90095

  • Phone+1 310-825-6708

  • Fax+1 310-825-6708

Dr. Federman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 2005 - 2008
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 2002 - 2005
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 2002
  • Williams College
    Williams CollegeB.A., English and Neuroscience, 1993 - 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2004 - 2026
  • Pediatric Hematology-Oncology
    American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • 2021 Los Angeles Magazine Top Doctors 2021
  • Voted Southern California Rising Star SuperDoctors.com, 2015
  • Voted Best Doctors BestDoctors.com, 2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Percutaneous Image guided core needle biopsies in children with bone and soft tissue tumors  
    Mitton B, Seeger LL, Eckardt MA, Motamedi K, Nelson SD, Eilber FC, Eckardt JJ, Federman N, J Pediatr Hematol Oncol, 1/1/2014
  • Giant cell tumor of bone in childhood: Clinical aspects and novel therapeutic targets Invited review  
    Federman N, Breyen E, Narasimhan V, Sodhi M, Dry SM, Chawla SP, Paediatr Drugs, 1/1/2014
  • Safety and efficacy of stereotactic body radiation therapy for pulmonary metastases from high-grade sarcomas  
    Mehta NM, Selch M, Federman N, Chmielowski B, Lee JM, Eilber FC, Wang P, Wu J, Agazaryan N, Lee P, Sarcoma, 1/1/2013
  • Join now to see all

Abstracts/Posters

  • Sclerostin expression and biologic function in skeletal sarcomas.
    Shen J, Shrestha S, La Chaud G, Asatrian G, Singh A, Federman N, Dry SM, Ting K, Chia S, James AW, Orthopedic Research Society Annual Meeting, 1/1/2016
  • Malignant transformation of dysplasia epiphysealis hemimelica (Trevor’s disease): The first reported case and recommendations for surveillance.
    Calvert G, Sato J, Federman N, Singh A, Femino D, Musculoskeletal Tumor Society Annual Meeting, 1/1/2015
  • A novel mutation in the HARS gene in a patient with infantile myofibromatosis.
    Baca N, Walsh A, Nelson SF, Federman N, Chang VY, American Society of Pediatric Hematology/Oncology Annual Meeting, 1/1/2015
  • Join now to see all

Lectures

  • Successful patient recruiting, consenting and retention on pediatric clinical trials. 
    1/1/2015
  • Approaches to Death and Dying in the Pediatric Oncology Patient. 
    1/1/2015
  • Osteosarcoma- what the orthopaedic surgeon needs to know. 
    1/1/2015
  • Join now to see all

Other

Press Mentions

  • Case Report Highlights Promising Approach for Treating Pediatric Thyroid Cancer
    Case Report Highlights Promising Approach for Treating Pediatric Thyroid CancerFebruary 7th, 2025
  • Drug Safe for Long-Term Use in Kids with Rare Cancer, Study Finds
    Drug Safe for Long-Term Use in Kids with Rare Cancer, Study FindsFebruary 4th, 2025
  • Unlocking the Potential of Patient-Derived Organoids for Personalized Sarcoma Treatment
    Unlocking the Potential of Patient-Derived Organoids for Personalized Sarcoma TreatmentSeptember 20th, 2024
  • Join now to see all

Professional Memberships

Other Languages

  • Spanish

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: